Business Context and Reporting Period
This Form 6-K filing by Evaxion Biotech A/S covers the month of November 2024, with a filing date of November 13, 2024. The report details amendments to the Company's Articles of Association resulting from share capital increases, the exercise of pre-funded warrants, and an at-the-market (ATM) offering of American Depositary Shares (ADSs).
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. Specific capitalization metrics include:
- ATM Offering Proceeds: Approximately $172,178 (net of fees and expenses) from the sale of 57,001 ADSs at an average price of $3.11 per ADS.
- Share Capital Increases:
- September 25, 2024: Increase of nominal DKK 1,070,000 (Total: DKK 56,850,546).
- September 30, 2024: Increase of nominal DKK 570,010 (Total: DKK 57,420,556).
- October 24, 2024: Increase of nominal DKK 1,240,000 (Total: DKK 58,660,556).
- Warrant Exercise Price: $1.4537 per ADS for pre-funded warrants.
- Remaining Prefunded Warrants: Confer the right to subscribe to 19,980,000 ordinary shares.
The filing text does not provide a clear value for total debt, liquidity ratios, or operating margins.
Material Changes
Material changes during the period include:
- Capital Structure: Multiple amendments to the Articles of Association to reflect increased share capital and procedural changes regarding warrant reservations.
- Warrant Adjustments: On October 3, 2024, the number of warrants granted to the European Investment Bank was increased by 22,091 to a total of 373,127.
- Currency Conversion: The subscription price for 9,726,898 warrants (granted Dec 21, 2023) and 37,500,000 warrants (granted Feb 1, 2024) was converted from USD to DKK.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, or specific risk factors beyond the standard incorporation by reference language. The document focuses strictly on corporate governance updates regarding capitalization and warrant terms.
Investor Verification Checklist
- Verify the total number of outstanding shares and ADSs following the capital increases effective September 25, September 30, and October 24, 2024.
- Confirm the remaining number of pre-funded warrants exercisable at $1.4537 per ADS (stated as 19,980,000 ordinary shares).
- Review the impact of the currency conversion (USD to DKK) on the subscription price for the 47,226,898 warrants mentioned.
- Check the status of the Capital Demand Sales Agreement with Jones Trading Institutional Services LLC for future ATM offering capacity.